101 related articles for article (PubMed ID: 21565522)
1. Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.
Rabian F; Lengline E; Rea D
Curr Hematol Malig Rep; 2019 Dec; 14(6):492-500. PubMed ID: 31760572
[TBL] [Abstract][Full Text] [Related]
2. Advances in the treatment of chronic myeloid leukemia.
Eiring AM; Khorashad JS; Morley K; Deininger MW
BMC Med; 2011 Aug; 9():99. PubMed ID: 21867560
[TBL] [Abstract][Full Text] [Related]
3. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
Noens L; Hensen M; Kucmin-Bemelmans I; Lofgren C; Gilloteau I; Vrijens B
Haematologica; 2014 Mar; 99(3):437-47. PubMed ID: 24598855
[TBL] [Abstract][Full Text] [Related]
4. Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.
Deremer DL; Katsanevas K; Ustun C
Cancer Manag Res; 2011 Mar; 3():65-78. PubMed ID: 21556318
[TBL] [Abstract][Full Text] [Related]
5. Analysis of drug transporter gene polymorphisms in an elderly patient with chronic myeloid leukemia successfully treated with intermittent low-dose dasatinib.
Nakamura Y; Hidaka D; Ogasawara R; Okada K; Sugita J; Sukehata A; Kitagawa K; Ota S; Imamura M
Geriatr Gerontol Int; 2023 Dec; 23(12):965-966. PubMed ID: 37920916
[No Abstract] [Full Text] [Related]
6. The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
Gallipoli P; Clark RE; Byrne J; Apperley JF; Milojkovic D; Foroni L; Goldman JM; O'Brien S
Br J Haematol; 2022 Mar; 196(6):e55-e57. PubMed ID: 34993961
[No Abstract] [Full Text] [Related]
7. The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.
Mauro MJ; Davis C; Zyczynski T; Khoury HJ
Ther Adv Hematol; 2015 Feb; 6(1):3-14. PubMed ID: 25642311
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Rosti G; Castagnetti F; Gugliotta G; Baccarani M
Nat Rev Clin Oncol; 2017 Mar; 14(3):141-154. PubMed ID: 27752053
[TBL] [Abstract][Full Text] [Related]
9. DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.
Flörcken A; Kopp J; Kölsch U; Meisel C; Dörken B; Pezzutto A; Westermann J
Hum Vaccin Immunother; 2016 May; 12(5):1117-23. PubMed ID: 26864050
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
Zheng Q; Wu H; Yu Q; Kim DH; Lipton JH; Angelini S; Soverini S; Vivona D; Takahashi N; Cao J
Pharmacogenomics J; 2015 Apr; 15(2):127-34. PubMed ID: 25245580
[TBL] [Abstract][Full Text] [Related]
11. Current management of chronic myeloid leukemia with tyrosine kinase inhibitors.
Haznedaroğlu IC
Turk J Haematol; 2013 Sep; 30(3):247-55. PubMed ID: 24385803
[TBL] [Abstract][Full Text] [Related]
12. Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers.
Ilardi G; Zambrano N; Merolla F; Siano M; Varricchio S; Vecchione M; De Rosa G; Mascolo M; Staibano S
Curr Med Chem; 2014; 21(14):1569-82. PubMed ID: 23992304
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation.
Piccaluga PP; Paolini S; Bertuzzi C; De Leo A; Rosti G
J Blood Med; 2012; 3():151-6. PubMed ID: 23226701
[TBL] [Abstract][Full Text] [Related]
14. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.
Gurion R; Gafter-Gvili A; Vidal L; Leader A; Ram R; Shacham-Abulafia A; Paul M; Ben-Bassat I; Shpilberg O; Raanani P
Haematologica; 2013 Jan; 98(1):95-102. PubMed ID: 22875617
[TBL] [Abstract][Full Text] [Related]
15. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.
Saunders NA; Simpson F; Thompson EW; Hill MM; Endo-Munoz L; Leggatt G; Minchin RF; Guminski A
EMBO Mol Med; 2012 Aug; 4(8):675-84. PubMed ID: 22733553
[TBL] [Abstract][Full Text] [Related]
16. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
Crit Rev Oncol Hematol; 2012 May; 82(2):159-70. PubMed ID: 21565522
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
18. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
Shami PJ; Deininger M
Leukemia; 2012 Feb; 26(2):214-24. PubMed ID: 21844872
[TBL] [Abstract][Full Text] [Related]
19. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
